CPT code 17271 represents the destruction of a malignant skin lesion sized 0.6 cm to 1.0 cm on areas including the scalp, neck, hands, feet, or genitalia using methods such as chemosurgery, cryosurgery, or electrosurgery. This code is used across outpatient and ambulatory care settings and is essential for billing targeted dermatologic procedures that manage small malignant cutaneous tumors. Nationally, correct use of this code affects coverage determinations, quality reporting, and reimbursement for skin cancer treatments performed in non-hospital settings.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical service settings, guidance on where this code applies, and a summary of common modifiers and related documentation considerations. The publication provides benchmarks and policy-relevant information where available, and highlights areas where input data was not provided. The goal is to clarify coding intent, support correct claim submission, and inform policy and administrative review related to outpatient destruction of malignant skin lesions.